Hilary E Faust1, John P Reilly2, Brian J Anderson3, Caroline A G Ittner3, Caitlyn M Forker3, Peggy Zhang3, Benjamin A Weaver3, Daniel N Holena4, Paul N Lanken3, Jason D Christie5, Nuala J Meyer2, Nilam S Mangalmurti2, Michael G S Shashaty5. 1. Allergy, Pulmonary and Critical Care Division, University of Wisconsin School of Medicine and Public Health, Madison, WI. Electronic address: hfaust@medicine.wisc.edu. 2. Pulmonary, Allergy and Critical Care Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Center for Translational Lung Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 3. Pulmonary, Allergy and Critical Care Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 4. Division of Traumatology, Surgical Critical Care, and Emergency Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Center for Resuscitation Science, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 5. Pulmonary, Allergy and Critical Care Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Center for Translational Lung Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Abstract
BACKGROUND: Critically ill patients who develop ARDS have substantial associated morbidity and mortality. Circulating mitochondrial DNA (mtDNA) released during critical illness causes endothelial dysfunction and lung injury in experimental models. This study hypothesized that elevated plasma mtDNA is associated with ARDS in critically ill patients with trauma and sepsis. METHODS: Plasma mtDNA concentrations were measured at ED presentation and approximately 48 h later in separate prospective cohorts of critically ill patients with trauma and sepsis. ARDS was classified according to the Berlin definition. The association of mtDNA with ARDS was tested by using multivariable logistic regression, adjusted for covariates previously shown to contribute to ARDS risk in each population. RESULTS: ARDS developed in 41 of 224 (18%) trauma patients and in 45 of 120 (38%) patients with sepsis. Forty-eight-hour mtDNA levels were significantly associated with ARDS (trauma: OR, 1.58/log copies/μL; 95% CI, 1.14-2.19 [P = .006]; sepsis: OR, 1.52/log copies/μL; 95% CI, 1.12-2.06 [P = .007]). Plasma mtDNA on presentation was not significantly associated with ARDS in either cohort. In patients with sepsis, 48-h mtDNA was more strongly associated with ARDS among those with a nonpulmonary infectious source (OR, 2.20/log copies/μL; 95% CI, 1.36-3.55 [P = .001], n = 69) than those with a pulmonary source (OR, 1.04/log copies/μL; 95% CI, 0.68-1.59 [P = .84], n = 51; P = .014 for interaction). CONCLUSIONS: Plasma mtDNA levels were associated with incident ARDS in two critical illness populations. Given supportive preclinical data, our findings suggest a potential link between circulating mtDNA and lung injury and merit further investigation as a potentially targetable mediator of ARDS.
BACKGROUND:Critically illpatients who develop ARDS have substantial associated morbidity and mortality. Circulating mitochondrial DNA (mtDNA) released during critical illness causes endothelial dysfunction and lung injury in experimental models. This study hypothesized that elevated plasma mtDNA is associated with ARDS in critically illpatients with trauma and sepsis. METHODS: Plasma mtDNA concentrations were measured at ED presentation and approximately 48 h later in separate prospective cohorts of critically illpatients with trauma and sepsis. ARDS was classified according to the Berlin definition. The association of mtDNA with ARDS was tested by using multivariable logistic regression, adjusted for covariates previously shown to contribute to ARDS risk in each population. RESULTS: ARDS developed in 41 of 224 (18%) traumapatients and in 45 of 120 (38%) patients with sepsis. Forty-eight-hour mtDNA levels were significantly associated with ARDS (trauma: OR, 1.58/log copies/μL; 95% CI, 1.14-2.19 [P = .006]; sepsis: OR, 1.52/log copies/μL; 95% CI, 1.12-2.06 [P = .007]). Plasma mtDNA on presentation was not significantly associated with ARDS in either cohort. In patients with sepsis, 48-h mtDNA was more strongly associated with ARDS among those with a nonpulmonary infectious source (OR, 2.20/log copies/μL; 95% CI, 1.36-3.55 [P = .001], n = 69) than those with a pulmonary source (OR, 1.04/log copies/μL; 95% CI, 0.68-1.59 [P = .84], n = 51; P = .014 for interaction). CONCLUSIONS: Plasma mtDNA levels were associated with incident ARDS in two critical illness populations. Given supportive preclinical data, our findings suggest a potential link between circulating mtDNA and lung injury and merit further investigation as a potentially targetable mediator of ARDS.
Authors: L K Metthew Lam; Sophia Murphy; Dimitra Kokkinaki; Alessandro Venosa; Scott Sherrill-Mix; Carla Casu; Stefano Rivella; Aaron Weiner; Jeongho Park; Sunny Shin; Andrew E Vaughan; Beatrice H Hahn; Audrey R Odom John; Nuala J Meyer; Christopher A Hunter; G Scott Worthen; Nilam S Mangalmurti Journal: Sci Transl Med Date: 2021-10-20 Impact factor: 19.319
Authors: Martin Ingi Sigurdsson; Hirotada Kobayashi; Karin Amrein; Kiichi Nakahira; Angela J Rogers; Mayra Pinilla-Vera; Rebecca M Baron; Laura E Fredenburgh; Jessica A Lasky-Su; Kenneth B Christopher Journal: Crit Care Date: 2022-10-19 Impact factor: 19.334
Authors: Davide Scozzi; Marlene Cano; Lina Ma; Dequan Zhou; Ji Hong Zhu; Jane A O'Halloran; Charles Goss; Adriana M Rauseo; Zhiyi Liu; Sanjaya K Sahu; Valentina Peritore; Monica Rocco; Alberto Ricci; Rachele Amodeo; Laura Aimati; Mohsen Ibrahim; Ramsey Hachem; Daniel Kreisel; Philip A Mudd; Hrishikesh S Kulkarni; Andrew E Gelman Journal: JCI Insight Date: 2021-02-22
Authors: Jon Hazeldine; Robert J Dinsdale; David N Naumann; Animesh Acharjee; Jonathan R B Bishop; Janet M Lord; Paul Harrison Journal: Burns Trauma Date: 2021-04-01